PDO-Derived Xenografts (PDOX) Model Development Services

Inquiry

In oncology drug discovery, preclinical models that seamlessly bridge in vitro high-throughput screening with in vivo pharmacologic validation are critical for translational success. Alfa Cytology offers comprehensive PDOX model development services designed to establish, expand, and characterize PDOX models by engrafting in vitro-expanded patient-derived organoids into immunodeficient mice. This innovative platform delivers a scalable, genetically tractable, and physiologically relevant in vivo model that accelerates drug efficacy validation, mechanism studies, and personalized therapy assessment.

Introduction to PDO-Derived Xenograft (PDOX) Model

PDO-derived xenograft (PDOX) development represents a paradigm shift in translational oncology, bridging the gap between organoid biology and in vivo pharmacology. PDOX models are generated by implanting in vitro-cultured PDOs (derived from surgical resections, biopsies, or cryopreserved organoid banks) into immunodeficient mice (e.g., NSG, BALB/c nude). These models combine the advantages of both platforms: the scalability, gene editability, and high-throughput compatibility of organoids with the tumor microenvironment, vascular integration, and systemic pharmacology of xenografts. Unlike conventional PDX models that require continuous patient tissue supply, PDOX can be serially regenerated from a single organoid line, enabling longitudinal studies, CRISPR-based genetic perturbations, and co-clinical trials with matched in vitro and in vivo data.

Fig. 1 PDO-Derived Xenografts (PDOX) Model. Fig. 1 Comparison of patient-derived organoids (PDO), patient-derived xenografts (PDX) and PDO-derived xenografts (PDOX). (Wang E, et al.; 2022)

Applications of PDO-Derived Xenograft (PDOX) Model

In Vivo Drug Efficacy Validation

Directly validates in vitro organoid screening hits (e.g., IC₅₀, synergy) in a physiologically intact tumor microenvironment with preserved patient-specific architecture and vascular integration, reducing false positives and improving translational predictability.

Mechanistic & Resistance Studies

Supports longitudinal studies of tumor evolution and acquired resistance using CRISPR-edited organoids serially regenerated from a single line, enabling in vivo validation of resistance mechanisms and relapse drivers.

Co-Clinical Trials & Personalized Therapy

Generates matched in vitro and in vivo drug response data from the same patient-derived line, directly correlating molecular features (NGS) with in vivo outcomes to support patient stratification and real-time therapeutic decisions.

Genetic Dependency & Target Validation

Combines organoid genetic tractability (CRISPR, cDNA overexpression, shRNA) with PDOX engraftment for definitive in vivo validation of oncogene addiction, tumor suppressor function, or synthetic lethality in a patient-relevant background.

Our Services

Alfa Cytology offers a comprehensive PDOX development service that transforms established patient-derived organoid lines into clinically relevant in vivo models for drug validation, mechanism studies, and co-clinical applications. By engrafting pre-characterized, gene-editable organoids, our platform generates PDOX models that retain authentic drug response profiles, genetic architecture, and patient-specific molecular features.

Workflow of PDO-Derived Xenograft (PDOX) Model Development

Tissue Acquisition & Processing

Receive surgical resection or biopsy specimen. Mechanically and enzymatically dissociate tumor tissue into single-cell suspensions.

PDO Culture Initiation

Embed viable tumor cells in BME/Matrigel and culture in cancer-type-specific, serum-free organoid media with growth factors (EGF, FGF, R-spondin, Noggin).

PDO Expansion & Maintenance

Maintain for 2–4 weeks to establish stable organoid lines. Characterize morphology and growth kinetics.

Organoid Banking & Quality Control

Cryopreserve early-passage PDO master cell banks. Perform mycoplasma and contamination testing.

Characterization & Validation

Perform H&E, IHC, IF, flow cytometry, STR genotyping, and NGS to confirm organoid identity and mutational profile.

Downstream Applications (Optional)

Conduct drug sensitivity testing (IC₅₀, synergy analysis), co-culture with immune cells, CRISPR gene editing, or resistance mechanism studies.

Supported Cancer Types

By integrating patient-derived organoid expansion with clinically relevant xenograft engraftment, our PDOX platform bridges in vitro screening and in vivo pharmacology. Supported by advanced tissue processing, organoid biobanking, and multi-parametric characterization, our platform ensures high engraftment rates and data reproducibility across cancer types, including but not limit:

Colorectal Cancer	Breast Cancer	Lung Cancer	Pancreatic Cancer
Gastric Cancer	Ovarian Cancer	Prostate Cancer	Liver Cancer

Alfa Cytology offers flexible PDOX development packages tailored to your needs, whether for in vivo efficacy validation, combination therapy assessment (e.g., with ATCs or checkpoint inhibitors), or CRISPR-based resistance studies. Our team is ready to assist with model selection, engraftment optimization, and data interpretation. Contact us to accelerate your oncology drug discovery with our PDOX platform.

Reference

Wang E, et al. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. J Natl Cancer Cent. 2022;2(4):263-276.

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.